Hide metadata

dc.date.accessioned2023-01-03T17:35:41Z
dc.date.available2023-01-03T17:35:41Z
dc.date.created2022-07-25T13:20:09Z
dc.date.issued2022
dc.identifier.citationFrigaard, Julie Mari Jensen, Janicke Liaaen Galtung, Hilde Hiorth, Marianne . The Potential of Chitosan in Nanomedicine: An Overview of the Cytotoxicity of Chitosan Based Nanoparticles. Frontiers in Pharmacology. 2022, 13, 1-19
dc.identifier.urihttp://hdl.handle.net/10852/98458
dc.description.abstractThe unique properties and applications of nanotechnology in targeting drug delivery, cosmetics, fabrics, water treatment and food packaging have received increased focus the last two decades. The application of nanoparticles in medicine is rapidly evolving, requiring careful investigation of toxicity before clinical use. Chitosan, a derivative of the natural polysaccharide chitin, has become increasingly relevant in modern medicine because of its unique properties as a nanoparticle. Chitosan is already widely used as a food additive and in food packaging, bandages and wound dressings. Thus, with an increasing application worldwide, cytotoxicity assessment of nanoparticles prepared from chitosan is of great interest. The purpose of this review is to provide an updated status of cytotoxicity studies scrutinizing the safety of chitosan nanoparticles used in biomedical research. A search in Ovid Medline from 23 March 1998 to 4 January 2022, with the combination of the search words Chitosan or chitosan , nanoparticle or nano particle or nanosphere or nanocapsule or nano capsule , toxicology or toxic or cytotoxic and mucosa or mucous membrane resulted in a total of 88 articles. After reviewing all the articles, those involving non-organic nanoparticles and cytotoxicity assays conducted exclusively on nanoparticles with anti-tumor effect (i.e., having cytotoxic effect) were excluded, resulting in 70 articles. Overall, the chitosan nanoparticles included in this review seem to express low cytotoxicity regardless of particle composition or cytotoxicity assay and cell line used for testing. Nonetheless, all new chitosan derivatives and compositions are recommended to undergo careful characterization and cytotoxicity assessment before being implemented on the market.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleThe Potential of Chitosan in Nanomedicine: An Overview of the Cytotoxicity of Chitosan Based Nanoparticles
dc.title.alternativeENEngelskEnglishThe Potential of Chitosan in Nanomedicine: An Overview of the Cytotoxicity of Chitosan Based Nanoparticles
dc.typeJournal article
dc.creator.authorFrigaard, Julie Mari
dc.creator.authorJensen, Janicke Liaaen
dc.creator.authorGaltung, Hilde
dc.creator.authorHiorth, Marianne
cristin.unitcode185,16,17,51
cristin.unitnameOral kirurgi og oral medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin2039365
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Frontiers in Pharmacology&rft.volume=13&rft.spage=1&rft.date=2022
dc.identifier.jtitleFrontiers in Pharmacology
dc.identifier.volume13
dc.identifier.doihttps://doi.org/10.3389/fphar.2022.880377
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn1663-9812
dc.type.versionPublishedVersion
cristin.articleid88377


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International